A Randomized Controlled Trial for Comparing the Effects of Dapagliflozin and Sitagliptin on Glucose Fluctuation and Control Measured by CGM in Chinese Type 2 Diabetes Mellitus

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900026285

Enrollment

Unknown

Registered

2019-09-29

Start date

2017-07-01

Completion date

Unknown

Last updated

2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

Group 2:Dapagliflozin

Group 1:Sitagliptin phosphate

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. newly diagnosed type 2 diabetes patients who have not used hypoglycemic agents; 2. aged 18-70 years old; 3. HbA1C 6.5% to 8.5%; 4. BMI 18.5 to 35 kg/m2.

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes; 2. acute complications of diabetes or combined with severe trauma, malnutrition, fasting, gastrointestinal disease; 3. severe cardiovascular and cerebrovascular diseases; 4. chronic kidney disease, serum creatinine clearance <30 mL / min or eGFR <60mL / min / 1.73 ? or severe liver disease; 5. may affect the disease or treatment between HbA1C and mean blood glucose, such as anemia (hematocrit, male <39%, female <36%), high erythrocyte turnover (reticular cell hyperactivity), blood loss or blood transfusion , High-dose vitamin C or erythropoietin treatment; 6. suffering from mental disorders, do not want or because of speech disorders can not fully understand or collaborators.

Design outcomes

Primary

Measure	Time frame
continuous glucose monitoring;	—

Countries

China

Contacts

Public ContactXin Yu-jing

First Affiliated Hospital of Harbin Medical University

764935373@qq.com+86 13614606412

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026